Latest news with #Viyash
Economic Times
3 days ago
- Business
- Economic Times
Carlyle portfolio firms SeQuent Scientific and Viyash Life get stock exchange nod for merger
SeQuent and Viyash move a step closer to merging, with Carlyle aiming to build a 2X scale business in animal health and pharma R&D. Carlyle-backed SeQuent Scientific and Viyash Life Sciences have secured stock exchange approvals for their merger. Next, they will approach NCLT. The merged entity aims to double in scale, with SeQuent's animal health focus complemented by Viyash's R&D and API strengths. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Carlyle portfolio firms SeQuent Scientific and Viyash Life Sciences have got stock exchange approvals for their planned merger. The former is listed while the latter is Scientific conveyed the development in a stock exchange filing on a next step, they will approach the national company law tribunal (NCLT) for holds a 53% stake in SeQuent and is the majority shareholder in privately held Viyash. SeQuent operates in the niche segment of Animal Health and markets its products in over 90 has built a strong presence in active pharmaceutical ingredients (API) and R&D space with strong business relations with leading companies around the globe.'We are pleased that our proposed merger with Viyash Life Sciences is progressing as planned. This merger will accelerate a compelling new journey for SeQuent as a leading player in animal health, and Viyash with its world-class R&D capabilities and USFDA-approved facilities,' said Rajaram Narayanan, managing director, SeQuent Scientific.'FY 2024–25 marks a pivotal year for us, with strong business results as we accelerate our growth and lay the foundation for the next phase of growth. With Viyash joining us, we are poised to become a significantly stronger business—2X in scale, capability, and opportunity.'Under the agreed merger terms, shareholders of Viyash will receive 56 SeQuent shares for every 100 Viyash shares Q4 FY25, the combined entity of SeQuent and Viyash delivered robust performance with consolidated revenues of Rs. 770 crore reflecting a 13.2% year-on-year growth. Adjusted earnings before interest, tax, depreciation and amortization stood at Rs. 122 crore, up 63.2%, with margins expanding by 485 basis points to 15.8%.
Time of India
3 days ago
- Business
- Time of India
Carlyle portfolio firms SeQuent Scientific and Viyash Life get stock exchange nod for merger
Carlyle portfolio firms SeQuent Scientific and Viyash Life Sciences have got stock exchange approvals for their planned merger. The former is listed while the latter is not. SeQuent Scientific conveyed the development in a stock exchange filing on Thursday. As a next step, they will approach the national company law tribunal (NCLT) for approval. Carlyle holds a 53% stake in SeQuent and is the majority shareholder in privately held Viyash. SeQuent operates in the niche segment of Animal Health and markets its products in over 90 countries. Viyash has built a strong presence in active pharmaceutical ingredients (API) and R&D space with strong business relations with leading companies around the globe. 'We are pleased that our proposed merger with Viyash Life Sciences is progressing as planned. This merger will accelerate a compelling new journey for SeQuent as a leading player in animal health, and Viyash with its world-class R&D capabilities and USFDA-approved facilities,' said Rajaram Narayanan, managing director, SeQuent Scientific. 'FY 2024–25 marks a pivotal year for us, with strong business results as we accelerate our growth and lay the foundation for the next phase of growth. With Viyash joining us, we are poised to become a significantly stronger business—2X in scale, capability, and opportunity.' Under the agreed merger terms, shareholders of Viyash will receive 56 SeQuent shares for every 100 Viyash shares held. In Q4 FY25, the combined entity of SeQuent and Viyash delivered robust performance with consolidated revenues of Rs. 770 crore reflecting a 13.2% year-on-year growth. Adjusted earnings before interest, tax, depreciation and amortization stood at Rs. 122 crore, up 63.2%, with margins expanding by 485 basis points to 15.8%.
